Expertise in
10
conditions

Dr. Elizabeth Gore

Radiation Oncology
Froedtert And The Medical College Of Wisconsin Froedtert Hospital
9200 W Wisconsin Ave, 
Milwaukee, WI 
Expertise in
10
conditions
Froedtert And The Medical College Of Wisconsin Froedtert Hospital
9200 W Wisconsin Ave, 
Milwaukee, WI 

Overview

Elizabeth Gore is a Radiation Oncologist in Milwaukee, Wisconsin. Dr. Gore is highly rated in 10 conditions, according to our data. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Lung Carcinoma, and Prostatectomy.

Her clinical research consists of co-authoring 68 peer reviewed articles and participating in 22 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Radiation Oncology

Licenses

Radiology in WI

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Children's Community Health
  • EPO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
View 1 Less Insurance Carrier -

Locations

Froedtert and the Medical College of Wisconsin Froedtert Hospital
9200 W Wisconsin Ave, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Completed
Publish Date: January 14, 2026
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Suspended
Publish Date: January 14, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2/Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
View 9 Less Clinical Trials

68 Total Publications

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 16, 2025
Similar Doctors
Expertise in
3
conditions
Dr. Colleen Lawton
Radiation Oncology
Expertise in
3
conditions
Dr. Colleen Lawton
Radiation Oncology

Froedtert And The Medical College Of Wisconsin Froedtert Hospital

9200 W Wisconsin Ave, 
Milwaukee, WI 
 (0.1 miles away)
414-805-4400
Languages Spoken:
English
See accepted insurances

Colleen Lawton is a Radiation Oncologist in Milwaukee, Wisconsin. Dr. Lawton is highly rated in 3 conditions, according to our data. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, and Prostatectomy.

William Pao
Expertise in
14
conditions
Dr. William Pao
Radiation Oncology
Expertise in
14
conditions
Dr. William Pao
Radiation Oncology

Aurora Medical Center Grafton

975 Port Washington Rd, 
Grafton, WI 
 (20.1 miles away)
262-329-5000
Languages Spoken:
English
See accepted insurances

William Pao is a Radiation Oncologist in Grafton, Wisconsin. Dr. Pao is highly rated in 14 conditions, according to our data. His top areas of expertise are Lung Cancer, EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Expertise in
26
conditions
Dr. Manpreet Bedi
Radiation Oncology
Expertise in
26
conditions
Dr. Manpreet Bedi
Radiation Oncology

Clinical Cancer Center-Froedtert Hospital

8800 W Doyne Ave, 
Milwaukee, WI 
 (0.1 miles away)
414-805-0505
Languages Spoken:
English
See accepted insurances

Manpreet Bedi is a Radiation Oncologist in Milwaukee, Wisconsin. Dr. Bedi is highly rated in 26 conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Rhabdomyosarcoma Embryonal, and Undifferentiated Pleomorphic Sarcoma.

Frequently Asked Questions about Dr. Elizabeth Gore

How do I make an appointment with Dr. Elizabeth Gore?

You can book an appointment with Dr. Elizabeth Gore by calling their office at 414-805-4400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Elizabeth Gore a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Elizabeth Gore is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Elizabeth Gore specialize in?

While Dr. Elizabeth Gore is a Radiation Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Elizabeth Gore participate in research or clinical trials?

Yes. Dr. Elizabeth Gore has published 68 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Elizabeth Gore's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Elizabeth Gore accept my insurance?

Dr. Elizabeth Gore accepts most major insurance plans, including Anthem BCBS and Aspirus Arise Health. We recommend calling the office directly at 414-805-4400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gore's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile